{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:33:43Z","timestamp":1709253223786},"reference-count":0,"publisher":"Global Cardiology Science and Practice","issue":"2","license":[{"start":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T00:00:00Z","timestamp":1708819200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["gcsp"],"abstract":"<jats:p>&#x0D;\n&#x0D;\n&#x0D;\n&#x0D;\n&#x0D;\n&#x0D;\nIntroduction: Iron deficiency (ID) is one of the most frequent comorbidities in patients with heart failure (HF) and is estimated to be present in up to 80% of acute patients regardless of their ejection fraction. Randomized controlled trials have shown that supplementary intravenous iron results in improved clinical outcomes; however, the current understanding of the effects of intravenous iron on morbidity and mortality remains limited.&#x0D;\nStudy and results: The meta-analysis pooled individual participant data from three randomized placebo-controlled trials of ferric carboxymaltose (FCM) in adult patients (n=4,501) with heart failure and iron deficiency (CONFIRM-HF, AFFIRM-AHF, and HEART-FID). FCM therapy significantly reduced the co-primary composite endpoint of total cardiovascular hospitalizations and cardiovascular death, with a rate ratio (RR 0.86; 95% CI 0.75 to 0.98; p=0.029). FCM therapy was associated with a 17% relative rate reduction in total cardiovascular hospitalizations (RR 0.83; 95% CI 0.73 to 0.96; p=0.009) and a 16% relative rate reduction in total heart failure hospitalizations (RR 0.84; 95% CI 0.71 to 0.98; p=0.025).&#x0D;\nLessons learned: The meta-analysis shows that in iron-deficient patients with heart failure and reduced or mildly reduced left ventricular ejection fraction, intravenous ferric carboxymaltose (FCM) is associated with a reduced risk of total cardiovascular hospitalization...&#x0D;\n&#x0D;\n&#x0D;\n&#x0D;\n&#x0D;\n&#x0D;\n<\/jats:p>","DOI":"10.21542\/gcsp.2024.10","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T19:47:53Z","timestamp":1708976873000},"source":"Crossref","is-referenced-by-count":0,"title":["Benefits of intravenous iron supplementation in heart failure"],"prefix":"10.21542","volume":"2024","author":[{"given":"Susy","family":"Kotit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8990","published-online":{"date-parts":[[2024,2,25]]},"container-title":["Global Cardiology Science and Practice"],"original-title":[],"link":[{"URL":"http:\/\/globalcardiologyscienceandpractice.com\/index.php\/gcsp\/article\/download\/703\/579","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/globalcardiologyscienceandpractice.com\/index.php\/gcsp\/article\/download\/703\/579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T19:49:21Z","timestamp":1709236161000},"score":1,"resource":{"primary":{"URL":"http:\/\/globalcardiologyscienceandpractice.com\/index.php\/gcsp\/article\/view\/703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,25]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,25]]}},"URL":"https:\/\/doi.org\/10.21542\/gcsp.2024.10","relation":{},"ISSN":["2305-7823"],"issn-type":[{"value":"2305-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,25]]}}}